VNRX

8-K - VOLITIONRX LTD (0000093314) (Filer)

HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, the NYSE American LLC (the "NYSE American") accepted the Company's plan of compliance for continued listing on the exchange. As previously reported, on February 6, 2026, the Company received a notice from the NYSE American stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses fro

HENDERSON, Nev., April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes that we have developed over the past 10 years. We have developed a range of cutting edge controls for our own products, and they should be very useful in a range of research settings. Given our shift to commercialization, we are now opening up these for sale through an online offering.Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented:"We are delighted to launch our extensive  range of off-the-shelf recombinant nucleosomes through this e

8-K - VOLITIONRX LTD (0000093314) (Filer)

8-K - VOLITIONRX LTD (0000093314) (Filer)

10-K - VOLITIONRX LTD (0000093314) (Filer)

8-K - VOLITIONRX LTD (0000093314) (Filer)

Conference call to discuss financial and operational results scheduled forWednesday, April 1 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025.  Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We set out over fifteen years ago to help save lives and improve outcomes for millions of

HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest ("NI") and Wallonie Entreprendre S.A. ("WE") in Belgium. Volition will use the proceeds from the financing for ongoing development of its Nu.Q® product portfolio, including taking forward its regulatory transition program for Nu.Q® NETs (from IVDD to IVDR), the continued research and development of a Lateral Flow product, specifically to enable access to its Nu.Q® NETs product in Low Income Countries and more.Mr. Nicolas Delahaye, Corporate Relations Manager, Namur

Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock JournalHENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a new clinical manuscript demonstrating that nucleosome levels, as measured by Volition's Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline are elevated in people that have experienced a traumatic event and are even higher in those patients that go on to have complications from the trauma. Principal Investigator and Senior Author, Myung S. Park, Professor of Surgery, Associate Medical Director of Research, Trauma Center, Director, Clinical Research Trials Unit, Center for Cl

HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients. Poster 244P : Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation1Joint lead author Dr. Pei-Hsing Chen, Assistant Professor, Surgical Department, National Taiwan University Hospital, Taipei City, Taiwan, said:"A key finding from this study was that measuring preoperative H3K27Me3-nucleos

Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference CallDate:  Wednesday, April 1, 2026Time:  8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (t

Blinded validation cohort achieves over 95% sensitivity for stage I & II cancers with 95% specificityCapture-Seq™ Targets $36 Billion TAM in Early Cancer Detection and MRD.HENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded validation cohort for the detection of cancer, including early stage cancer using its breakthrough Capture-Seq™ technology.   Dr. Jake Micallef, Chief Scientific Officer, Volition, commented:"As we reported previously, Volition has developed a new liquid biopsy method, Capture-Seq™, which enriches and purifies p

4 - VOLITIONRX LTD (0000093314) (Issuer)

4 - VOLITIONRX LTD (0000093314) (Issuer)

4 - VOLITIONRX LTD (0000093314) (Issuer)

4 - VOLITIONRX LTD (0000093314) (Issuer)

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1". The biggest problem facing liquid biopsy worldwide is that the vast majori

HENDERSON, Nev., March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q® Vet Cancer Test with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems") in Japan, allowing use of full automation rather than manual plates in central laboratories. Junichi Makino, President and Representative Director at Fujifilm Vet Systems, said: "We are excited to be the first in the world to utilize this centralized lab automation for the Nu.Q® Vet Cancer Test, this is a big step forward from the current use of manual plates."S

4 - VOLITIONRX LTD (0000093314) (Issuer)

4 - VOLITIONRX LTD (0000093314) (Issuer)

4 - VOLITIONRX LTD (0000093314) (Issuer)

4 - VOLITIONRX LTD (0000093314) (Issuer)

4 - VOLITIONRX LTD (0000093314) (Issuer)

4 - VOLITIONRX LTD (0000093314) (Issuer)